At risk of being moderated again, I have reinstated below (data sourced from Venture annual report).
BOD '22 S/T Remuneration vs L/T performance benefits- Note that total remuneration was lower in '22, however short term base payment higher. In other words, ensuring they are paid regardless of project success. So how are their payments linked to project/activity success. Come on BOD prove me wrong and participate in share offer.
Also, how much of $3m CR will be left after SPP manager fee? No costings available?
How WILL, not "intend to use", limited funds be prioritized across all their projects? Just some of the many unanswered questions that genuine S/Hs expect but not supplied.
At risk of being moderated again, I have reinstated below (data...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
-0.001(8.33%) |
Mkt cap ! $29.39M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.1¢ | $47.96K | 4.365M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 8709595 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 5473603 | 13 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| CRI (ASX) Chart |